Minireviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Ophthalmol. Aug 12, 2015; 5(3): 133-141
Published online Aug 12, 2015. doi: 10.5318/wjo.v5.i3.133
Diabetic macular edema: Efficacy and safety of anti-vascular endothelial growth factor therapy
Emre Güler, Ramazan Yağcı
Emre Güler, Erciş State Hospital, Eye Clinic, 65400 Van, Turkey
Ramazan Yağcı, Department of Ophthalmology, Pamukkale University, Medical School, 20160 Denizli, Turkey
Author contributions: Güler E and Yağcı R contributed equally to this work.
Conflict-of-interest statement: No authors have any conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ramazan Yağcı, MD, Department of Ophthalmology, Pamukkale University, Medical School, Çamlaraltı Mahallesi, 20160 Denizli, Turkey. ramazanyagci@yahoo.com
Telephone: +90-312-2035555 Fax: +90-312-2035028
Received: December 1, 2014
Peer-review started: December 2, 2014
First decision: February 7, 2015
Revised: May 24, 2015
Accepted: May 27, 2015
Article in press: May 28, 2015
Published online: August 12, 2015
Processing time: 259 Days and 4.4 Hours
Core Tip

Core tip: Diabetic retinopathy is one of the prominent reasons of vision loss in the industrial countries. Among these patients, diabetic macular edema (DME) is the main reason of vision impairment. Previous studies have shown that vascular endothelial growth factor (VEGF) has a major role in the pathogenesis of diabetic retinopathy and DME, as well as demonstrated favorable results for DME treatment. This review summarizes the outcomes of clinical trials that evaluated anti-VEGF agents including pegaptanib, ranibizumab, bevacizumab, and aflibercept in DME treatment.